CA2701215C - Articular cartilage gene therapy with recombinant vector encoding bmp-7 - Google Patents

Articular cartilage gene therapy with recombinant vector encoding bmp-7 Download PDF

Info

Publication number
CA2701215C
CA2701215C CA2701215A CA2701215A CA2701215C CA 2701215 C CA2701215 C CA 2701215C CA 2701215 A CA2701215 A CA 2701215A CA 2701215 A CA2701215 A CA 2701215A CA 2701215 C CA2701215 C CA 2701215C
Authority
CA
Canada
Prior art keywords
seq
bmp
leu
polypeptide
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2701215A
Other languages
English (en)
French (fr)
Other versions
CA2701215A1 (en
Inventor
Laurent Bernard Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of CA2701215A1 publication Critical patent/CA2701215A1/en
Application granted granted Critical
Publication of CA2701215C publication Critical patent/CA2701215C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/51Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/10Animals modified by protein administration, for non-therapeutic purpose
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/102Caprine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA2701215A 2007-10-05 2008-10-07 Articular cartilage gene therapy with recombinant vector encoding bmp-7 Expired - Fee Related CA2701215C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/867,919 US7846428B2 (en) 2007-10-05 2007-10-05 Articular cartilage gene therapy with recombinant vector encoding BMP-7
US11/867,919 2007-10-05
PCT/US2008/079090 WO2009046464A1 (en) 2007-10-05 2008-10-07 Articular cartilage gene therapy with recombinant vector encoding bmp-7

Publications (2)

Publication Number Publication Date
CA2701215A1 CA2701215A1 (en) 2009-04-09
CA2701215C true CA2701215C (en) 2016-05-17

Family

ID=40276182

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2701215A Expired - Fee Related CA2701215C (en) 2007-10-05 2008-10-07 Articular cartilage gene therapy with recombinant vector encoding bmp-7

Country Status (7)

Country Link
US (1) US7846428B2 (enExample)
EP (1) EP2205743B1 (enExample)
JP (1) JP2012505151A (enExample)
CN (1) CN102027114A (enExample)
BR (1) BRPI0817753A8 (enExample)
CA (1) CA2701215C (enExample)
WO (1) WO2009046464A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084145A2 (en) * 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
RU2516951C1 (ru) * 2013-03-01 2014-05-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарёва" Способ профилактики посттравматического артроза коленного сустава
HRP20181913T1 (hr) 2013-07-18 2019-01-11 Xalud Therapeutics, Inc. Sastav za liječenje upale bolesti zglobova
WO2015035395A1 (en) * 2013-09-09 2015-03-12 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells
RU2771490C2 (ru) 2016-01-13 2022-05-05 Мериал, Инк. Рекомбинантные aav векторы, экспрессирующие остеопротективные гены, включая has2 и лубрицин, пригодные при лечении остеоартрита и сходных заболеваний суставов у млекопитающих
US10617739B2 (en) * 2016-04-13 2020-04-14 Universiteit Maastricht Method for the treatment or prevention of osteoarthritis
AU2018258100B2 (en) * 2017-04-27 2022-04-14 Eli Lilly And Company Variants of human BMP7 protein
US11246836B2 (en) * 2018-05-17 2022-02-15 Bluelight Pharmatech Co., Ltd. Intramuscular depot of decoquinate compositions and method of prophylaxis and treatment thereof
CN112168793A (zh) * 2020-10-26 2021-01-05 辰欣药业股份有限公司 一种盐酸氨溴索口腔崩解片及其制备方法
US20240316219A1 (en) * 2021-05-03 2024-09-26 North Carolina State University Compositions and methods related to the treatment of ocular diseases in equines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US6159464A (en) * 1990-12-20 2000-12-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
WO2002083080A2 (en) * 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
US20040167088A1 (en) * 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2004083434A1 (en) * 2003-03-17 2004-09-30 The University Of Hong Kong A combined adeno-associated virus and adenovirus cocktail gene delivery system for high effiency gene expression without eliciting immune response in immuno-competent subjects
WO2005007098A2 (en) * 2003-07-08 2005-01-27 New York University Nucleic acid therapy to enhance cartilage repair
EP1660663A4 (en) * 2003-08-12 2007-07-11 Brigham & Womens Hospital METHOD AND COMPOSITIONS FOR TISSUE REPAIR
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
EP1978994B1 (en) * 2005-12-22 2012-02-01 Janssen Biotech, Inc. Bmp-7 variant compositions, methods and uses

Also Published As

Publication number Publication date
CA2701215A1 (en) 2009-04-09
CN102027114A (zh) 2011-04-20
BRPI0817753A8 (pt) 2017-09-26
US7846428B2 (en) 2010-12-07
BRPI0817753A2 (pt) 2015-03-24
EP2205743A1 (en) 2010-07-14
EP2205743B1 (en) 2017-07-19
WO2009046464A8 (en) 2012-04-26
WO2009046464A1 (en) 2009-04-09
JP2012505151A (ja) 2012-03-01
US20090093427A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
CA2701215C (en) Articular cartilage gene therapy with recombinant vector encoding bmp-7
US20240254454A1 (en) Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals
AU2016277608B2 (en) Peptides and compositions for treatment of joint damage
US20240327479A1 (en) Il-1ra cdnas
Evans et al. The 2003 Nicolas Andry award: orthopaedic gene therapy
CN1295617A (zh) 血管生成因子-血管内皮细胞生长因子vegf的突变体
JP5856117B2 (ja) 細胞シグナル伝達タンパク質nell1を用いた、創傷治癒及び筋再生の促進方法
US20030091536A1 (en) In vivo treatment of joint disease using interleukin-1
JPH09510357A (ja) 酸性繊維芽細胞成長因子(aFGF)をコードする組み換えアデノウィルス
Evans et al. Potential applications of gene therapy in sports medicine
AU2915801A (en) In vivo treatment of joint disease using interleukin-1 receptor antagonists

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130513

MKLA Lapsed

Effective date: 20201007